How much does NINLARO (Ixazomib Citrate Capsules) Cost& price without insurance in China?
NINLARO® is the commercial brand name of Ixazomib Citrate Capsules, an orally active, reversible proteasome inhibitor developed by Takeda Pharmaceuticals. It exerts anti-tumor activity by inhibiting the chymotrypsin-like activity of the 20S proteasome, thereby disrupting the ubiquitin-proteasome pathway, inducing endoplasmic reticulum stress, and triggering apoptosis in multiple myeloma cells.
Main Indications
In combination with lenalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Common Side Effects
Common adverse reactions: Diarrhea, constipation, thrombocytopenia, neutropenia, nausea, peripheral neuropathy, peripheral edema, vomiting, back pain, and upper respiratory tract infection.
Laboratory abnormalities: Decreased platelet count, decreased neutrophil count, decreased lymphocyte count, and decreased hemoglobin.
Severe but manageable risks: Thrombocytopenia with bleeding events, peripheral neuropathy, gastrointestinal toxicity, and hepatotoxicity.
Approval Status in China
NINLARO® (Ixazomib Citrate Capsules, 4mg) was officially approved for marketing in China in April 2018. It is currently a prescription drug included in China’s Category B medical insurance.
Buy NINLARO (Ixazomib Citrate Capsules) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
